Michael L Power

US Patent:

6627739, Sep 30, 2003

Filed:

Nov 28, 2000

Appl. No.:

09/724566

Inventors:

John P. Anderson - San Francisco CA
Guriqbal Basi - Palo Alto CA
Minh Tam Doan - Hayward CA
Normand Frigon - Milbrae CA
Varghese John - San Francisco CA
Michael Power - Fremont CA
Sukanto Sinha - San Francisco CA
Gwen Tatsuno - Oakland CA
Jay Tung - Belmont CA
Shuwen Wang - Hersey PA
Lisa McConlogue - Burlingame CA

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07K 1640

US Classification:

5303879, 5303881, 53038826, 5303891, 5303892

Abstract:

Disclosed are various forms of an active, isolated -secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimers disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (-APPwt and -APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate -secretase. Inhibitors of -secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimers disease.

US Patent:

7067271, Jun 27, 2006

Filed:

Nov 28, 2000

Appl. No.:

09/724571

Inventors:

John P. Anderson - San Francisco CA, US
Guriqbal Basi - Palo Alto CA, US
Minh Tam Doan - Hayward CA, US
Normand Frigon - Milbrae CA, US
Varghese John - San Francisco CA, US
Michael Power - Fremont CA, US
Sukanto Sinha - San Francisco CA, US
Gwen Tatsuno - Oakland CA, US
Jay Tung - Belmont CA, US
Shuwen Wang - Hersey PA, US
Lisa McConlogue - Burlingame CA, US

Assignee:

Elan Pharmaceuticals, Inc. - So. San Francisco CA

International Classification:

C12Q 1/37
C12N 9/50
C12N 9/64
C12N 15/63

US Classification:

435 23, 435219, 435226, 435455

Abstract:

Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.

US Patent:

7109017, Sep 19, 2006

Filed:

Nov 28, 2000

Appl. No.:

09/724569

Inventors:

John P. Anderson - San Francisco CA, US
Guriqbal Basi - Palo Alto CA, US
Minh Tam Doan - Hayward CA, US
Normand Frigon - Milbrae CA, US
Varghese John - San Francisco CA, US
Michael Power - Fremont CA, US
Sukanto Sinha - San Francisco CA, US
Gwen Tatsuno - Oakland CA, US
Jay Tung - Belmont CA, US
Shuwen Wang - Hersey PA, US
Lisa McConlogue - Burlingame CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C12N 9/82
C12N 5/06
C07H 21/04
A23J 1/00
C12P 21/06

US Classification:

435226, 536 232, 536 234, 435 691, 4353201, 43525233, 435348, 4352542, 435325, 4352523, 530350, 530412, 5303873

Abstract:

Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.

US Patent:

7115410, Oct 3, 2006

Filed:

Nov 28, 2000

Appl. No.:

09/723722

Inventors:

John P. Anderson - San Francisco CA, US
Guriqbal Basi - Palo Alto CA, US
Minh Tam Doan - Hayward CA, US
Normand Frigon - Milbrae CA, US
Varghese John - San Francisco CA, US
Michael Power - Fremont CA, US
Sukanto Sinha - San Francisco CA, US
Gwen Tatsuno - Oakland CA, US
Jay Tung - Belmont CA, US
Shuwen Wang - Hersey PA, US
Lisa McConlogue - Burlingame CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C12N 9/64
C12N 15/00
C12N 5/00
C08G 33/66
C07H 21/04

US Classification:

435226, 530300, 4353201, 435325, 536 232

Abstract:

Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.

US Patent:

7252963, Aug 7, 2007

Filed:

Mar 25, 2005

Appl. No.:

11/090866

Inventors:

John P. Anderson - San Francisco CA, US
Guriqbal Basi - Palo Alto CA, US
Minh Tam Doan - Hayward CA, US
Normand Frigon - Milbrae CA, US
Varghese John - San Francisco CA, US
Michael Power - Fremont CA, US
Sukanto Sinha - San Francisco CA, US
Gwen Tatsuno - Oakland CA, US
Jay Tung - Belmont CA, US
Shuwen Wang - Hershey PA, US
Lisa McConlogue - Burlingame CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C12N 9/64
C12N 9/50
C12Q 1/37
C07K 1/00

US Classification:

435 23, 435226, 435219, 530350

Abstract:

Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.

US Patent:

7276349, Oct 2, 2007

Filed:

Mar 25, 2005

Appl. No.:

11/090872

Inventors:

John P. Anderson - San Francisco CA, US
Guriqbal Basi - Palo Alto CA, US
Minh Tam Doan - Hayward CA, US
Normand Frigon - Milbrae CA, US
Varghese John - San Francisco CA, US
Michael Power - Fremont CA, US
Sukanto Sinha - San Francisco CA, US
Gwen Tatsuno - Oakland CA, US
Jay Tung - Belmont CA, US
Shuwen Wang - Hershey PA, US
Lisa McConlogue - Burlingame CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C12Q 1/37
C12N 9/64
C07K 1/00

US Classification:

435 23, 435226, 530350

Abstract:

Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.

US Patent:

7427478, Sep 23, 2008

Filed:

Feb 28, 2005

Appl. No.:

11/069377

Inventors:

John P. Anderson - San Francisco CA, US
Guriqbal Basi - Palo Alto CA, US
Minh Tam Doan - Hayward CA, US
Normand Frigon - Milbrae CA, US
Varghese John - San Francisco CA, US
Michael Power - Fremont CA, US
Sukanto Sinha - San Francisco CA, US
Gwen Tatsuno - Oakland CA, US
Jay Tung - Belmont CA, US
Shuwen Wang - Hershey PA, US
Lisa McConlogue - Burlingame CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C12Q 1/37
C12N 5/00
C12N 9/64
A64K 38/00
C07K 1/00

US Classification:

435 6, 435325, 435 721, 435226, 435 23, 530300, 530350, 536 232

Abstract:

Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.

US Patent:

7456007, Nov 25, 2008

Filed:

Dec 24, 1999

Appl. No.:

09/471669

Inventors:

John P. Anderson - San Francisco CA, US
Guriqbal Basi - Palo Alto CA, US
Minh Tam Doan - Hayward CA, US
Normand Frigon - Millbrae CA, US
Varghese John - San Francisco CA, US
Michael Power - Fremont CA, US
Sukanto Sinha - San Francisco CA, US
Gwen Tatsuno - Oakland CA, US
Jay Tung - Belmont CA, US
Shuwen Wang - Hershey PA, US
Lisa McConlogue - Burlingame CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C12N 9/64
C12N 15/00
C12N 5/00
C12P 21/06
C12Q 1/68

US Classification:

435226, 4353201, 435325, 435 691, 435 6, 435 23, 4352523, 4352524, 435348, 536 232, 536412

Abstract:

Disclosed is an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (APP and APPsw) are also disclosed. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.